Personalized Medicines In Oncology Market By Tumor 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Personalized Medicines In Oncology Market
Personalized Medicines In Oncology Market: By Tumor (Genomics, Proteomics, Metabolomics) End User (Hospitals, Research Centers, Governmental institutions) Technology (Next-Generation Sequencing, PCR, Others) By Occurrence- Forecast(2016-2021)
Report Code : HCR 0097
Updated Date: 14 January, 2016  

Copies sold

    Client Rating

  • Report Description
  • Table of Contents
  • Customization Options
1. Market Overview
2. Executive Summary
3. Personalized Medicines In Oncology Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Personalized Medicines In Oncology Forces
   4.1. Market Drivers
   4.2. Market Constraints & Challenges
   4.3. Attractiveness of the Personalized Medicines In Oncology Market
      4.3.1. Power of Suppliers
      4.3.2. Threats From New Entrants
      4.3.3. Power of Buyer
      4.3.4. Threat From Substitute Product
      4.3.5. Degree of Competition
5. Personalized Medicines In Oncology -Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunity Analysis
   5.4. Product Life Cycle
   5.5. Suppliers and Distributors
6. Personalized Medicines In Oncology- By Tumore Type
   6.1. Genomics
   6.2. Proteomics
   6.3. Metabolomics
   6.4. Epigenetics
7. Personalized Medicines In Oncology- By Service
   7.1. Molecular Oncopathology
   7.2. Genome Diagnostics
   7.3. Radiation Therapy
   7.4. Oncology Testing
   7.5. Chemotherapy
   7.6. Others
8. Personalized Medicines In Oncology- By Occurence
   8.1. Colorectal/ stomach/ esophageal
   8.2. Ovarian
   8.3. Lung
   8.4. Brest
   8.5. Sarcoma
   8.6. Pancreatic
   8.7. Cancer
   8.8. Mesothelioma
   8.9. Others
9. Personalized Medicines In Oncology- By Technology
   9.1. Next-Generation Sequencing
   9.2. Fluorescence/ Chromogenic In Situ Hybridization
   9.3. Immunohistochemistry
   9.4. Microarray
   9.5. Quantitative PCR
   9.6. High Throughput SNP Analysis
   9.7. Others
10. Personalized Medicines In Oncology- By End User
   10.1. Research Centers
   10.2. Governmental Institutions
   10.3. Hospitals
   10.4. others
11. Personalized Medicines In Oncology- Geography
   11.1.  Americas
      11.1.1. U.S.
      11.1.2. Canada
      11.1.3. Brazil
      11.1.4. Others
   11.2. Europe
      11.2.1. U.K.
      11.2.2. Germany
      11.2.3. Italy
      11.2.4. France
      11.2.5. Others
   11.3. Asia Pacific
      11.3.1. China 
      11.3.2. Japan
      11.3.3. Australia & New Zealand
      11.3.4. Others
   11.4. Rest of The World (RoW)
      11.4.1. Middle East
      11.4.2. Africa
12. Personalized Medicines In Oncology Entropy
   12.1. New Product Developments
   12.2. Product Launches, JVs, Mergers and Acquisitions
13. Company Profiles
   13.1. Agendia Nv
   13.2. Allere Laboratory
   13.3. Alpha Genomix
   13.4. Ariana Pharma
   13.5. Biocrates
   13.6. Biodiscovery
   13.7. Biotheranostics
   13.8. Boreal Genomics, Inc.
   13.9. Caris Life Sciences
   13.10. Chordoma Foundation
   13.11. CompanionDx
   13.12. Cypher Genomics
   13.13. deCode Genetics
   13.14. Diploid
   13.15. DNA Link
   13.16. Edge Bio
   13.17. Foundation Medicine
   13.18. Fulgent Diagnostics
   13.19. Gene TLC
   13.20. GenebyGene
   13.21. Genomic Engenharia Molecular
   13.22. Genomic Health, Inc.
   13.23. Illumina, Inc. 
   13.24. Life Technologies Corporation
   13.25. MapMyGenome
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
14. Appendix

   14.1. Abbreviations
   14.2. Sources
   14.3. Research Methodology
   14.4. Bibliography
   14.5. Compilation of Expert Insights
A Personalized medicine application has the largest network, mainly due to high demand for the effective cancer treatment. Apart from the huge potential of the market in personalized medicine and diagnostic segments; it also has a strong value and the vast expansion opportunities in its application such as biomarker, discovery, cancer and research applications. A number of new tools and services are offered by the various biotechnology medical companies for cancer/tumor profiling which is greatly served a cancer screening and the diagnostic. These tools and services are speeding up the development in the cancer therapeutics field and help in boosting the growth of the personalized medicine market.

A significant tool to achieve Personalized Medicine is the availability of repositories of freely accessible databases. Large databases are formed containing information from genomic, transcriptomic, and proteomic analyses which is available for global access and data processing. Some of these include the Cancer Genome Anatomy Project, the Single Nucleotide Polymorphism Database, in addition to many others. Bioinformatics algorithms can then be used to integrate a patient's clinical information and the genetic profiles of their tumor to predict the relationships of certain molecular changes to the cancer.

Standardization of Personalized medicine includes several characteristics including the type of sample to be analyzed, the suitable methods of sample collection and storage, the selection of the target genes/proteins to be tested, the platform to be used, best experimental conditions, and the interpretation of tests. There are specific quality standards for different laboratories, and test validations will be required with external quality assurance protocols.

There are different approaches and tools available for molecular Personalized Medicine testing. A large array of techniques can be used for Personalized Medicine. Commonly used techniques include PCR, fluorescence in situ hybridization and sequencing. Recently, the completion of the human genome project opened a new opportunities for Personalize Medicine analysis by using high-throughput analysis. These include microarray, mass spectrometry, second-generation sequencing, array comparative genomic hybridization, and high-throughput SNP analysis, among others. A common trend among these tools is their ability to simultaneously analyze hundreds or thousands of targets. This multipara metric approach is likely to improve the sensitivity, specificity, and accuracy of new biomarkers. In addition to acceleration of biomarker discovery, high-throughput analysis allows a better understanding of interaction between different molecules in the pathogenesis of cancer.

Personalized Medicines In Oncology

The overall market generated revenue of $xx m in 2015 and is expected to grow with CAGR of xx% throughout the forecast period to generate $xx m by 2021. The Major players are focusing on marketing their products in emerging markets such as India, Japan, Brazil, and China. Currently Americas and Europe region dominate the overall market by contributing to xx% of the overall revenue. These regions are growing with CAGR of xx% and xx% respectively throughout the forecast period.
The Key biotechnology and pharmaceutical companies such as:
  • Caris Life Sciences (U.S.)
  • Proteome Sciences PLC (U.K.)
  • Life Technologies (U.S.)
  • Boreal Genomics, Inc. (U.S.)
  • Oxford Gene Technology Ltd. (OGT) (U.K.)
  • Precision Therapeutics, Inc. (U.S.)

Among others, are undertaking various strategically decisions such as collaborating and partnering with each other as well as with research universities to develop cancer profiling products.
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports